title: Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence.
abstract: The wars in Iraq and Afghanistan are associated with high rates of post-traumatic stress disorder (PTSD) and comorbid alcohol use disorders. The pharmacotherapy of these comorbid conditions has received relatively little study. The current study compared the serotonin uptake inhibitor, paroxetine, to the norepinephrine uptake inhibitor, desipramine. It also evaluated the adjunctive efficacy of the Food and Drug Administration (FDA)-approved alcoholism pharmacotherapy, naltrexone, relative to placebo. Four groups of predominately male veterans (n=88) meeting current diagnostic criteria for both alcohol dependence (AD) and PTSD were randomly assigned under double-blind conditions to one of four groups: paroxetine+naltrexone; paroxetine+placebo; desipramine+naltrexone; desipramine+placebo. Main outcome measures included standardized scales that assessed symptoms of PTSD and alcohol consumption. Paroxetine did not show statistical superiority to desipramine for the treatment of PTSD symptoms. However, desipramine was superior to paroxetine with respect to study retention and alcohol use outcomes. Naltrexone reduced alcohol craving relative to placebo, but it conferred no advantage on drinking use outcomes. Although the serotonin uptake inhibitors are the only FDA-approved medications for the treatment of PTSD, the current study suggests that norepinephrine uptake inhibitors may present clinical advantages when treating male veterans with PTSD and AD. However, naltrexone did not show evidence of efficacy in this population. This study was registered with ClinicalTrials.gov, registration number NCT00338962 and URL: http://clinicaltrials.gov/ct2/show/NCT00338962?term=desipramine+AND+alcohol+dependence+AND+depression&recr=Closed&rank=1.
authors.affiliation: VA Connecticut Healthcare System, Yale University School of Medicine, West Haven, CT, USA. ismene.petrakis@yale.edu
authors.forename: Ismene L
authors.initials: IL
authors.lastname: Petrakis
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Ralevski
authors.forename: Nitigna
authors.initials: N
authors.lastname: Desai
authors.forename: Louis
authors.initials: L
authors.lastname: Trevisan
authors.forename: Ralitza
authors.initials: R
authors.lastname: Gueorguieva
authors.forename: Bruce
authors.initials: B
authors.lastname: Rounsaville
authors.forename: John H
authors.initials: JH
authors.lastname: Krystal
mesh_terms: D000322:Adrenergic Agonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000437:Alcoholism / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage* / Q000009:adverse effects; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D016896:Treatment Outcome; D014728:Veterans / Q000523:psychology*
chemical_list: D000322:Adrenergic Agonists; D000928:Antidepressive Agents; D017366:Serotonin Receptor Agonists; D009271:Naltrexone
references.citation: Lancet. 2010 May 22;375(9728):1783-97
references.pmid: 20471076
references.citation: Biol Psychiatry. 2004 Nov 15;56(10):785-92
references.pmid: 15556124
references.citation: JAMA. 2006 May 3;295(17):2003-17
references.pmid: 16670409
references.citation: Psychopharmacol Bull. 1986;22(2):343-81
references.pmid: 3774930
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1158-65
references.pmid: 17015818
references.citation: J Clin Psychiatry. 2008 Apr;69(4):520-5
references.pmid: 18278987
references.citation: Am J Psychiatry. 2001 Dec;158(12):1982-8
references.pmid: 11729013
references.citation: Biol Psychiatry. 2006 Oct 1;60(7):777-83
references.pmid: 17008146
references.citation: JAMA. 2000 Apr 12;283(14):1837-44
references.pmid: 10770145
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):169-80
references.pmid: 19141307
references.citation: AIDS Care. 2004;16 Suppl 1:S97-120
references.pmid: 15736824
references.citation: N Engl J Med. 2004 Jul 1;351(1):13-22
references.pmid: 15229303
references.citation: J Clin Psychiatry. 2007 May;68(5):711-20
references.pmid: 17503980
references.citation: J Clin Psychopharmacol. 2006 Apr;26(2):152-6
references.pmid: 16633143
references.citation: Curr Opin Psychiatry. 2008 May;21(3):242-6
references.pmid: 18382221
references.citation: Recent Dev Alcohol. 1988;6:27-48
references.pmid: 3283857
references.citation: Arch Gen Psychiatry. 2004 Mar;61(3):310-7
references.pmid: 14993119
references.citation: JAMA. 2006 Mar 1;295(9):1023-32
references.pmid: 16507803
references.citation: Arch Gen Psychiatry. 1995 Dec;52(12):1048-60
references.pmid: 7492257
references.citation: J Trauma Stress. 2001 Jul;14(3):445-52
references.pmid: 11534876
references.citation: J Clin Psychiatry. 1995 Nov;56(11):502-5
references.pmid: 7592501
references.citation: Addict Behav. 1995 Sep-Oct;20(5):643-55
references.pmid: 8712061
references.citation: Annu Rev Med. 1999;50:453-68
references.pmid: 10073289
references.citation: J Clin Psychiatry. 2001 Nov;62(11):860-8
references.pmid: 11775045
references.citation: Arch Gen Psychiatry. 1985 May;42(5):473-81
references.pmid: 2985014
references.citation: Am J Psychiatry. 1989 Apr;146(4):513-6
references.pmid: 2648867
references.citation: Addict Behav. 2003 Dec;28(9):1717-30
references.pmid: 14656555
references.citation: J Clin Psychiatry. 2001;62 Suppl 20:26-31
references.pmid: 11584872
references.citation: Recent Dev Alcohol. 1988;6:49-68
references.pmid: 3283864
references.citation: JAMA. 1996 Mar 13;275(10):761-7
references.pmid: 8598592
references.citation: Addict Behav. 2004 Nov;29(8):1665-72
references.pmid: 15451135
references.citation: Arch Gen Psychiatry. 1996 Mar;53(3):225-31
references.pmid: 8611059
references.citation: N Engl J Med. 2001 Dec 13;345(24):1734-9
references.pmid: 11742047
references.citation: Alcohol Clin Exp Res. 1996 Dec;20(9):1534-41
references.pmid: 8986200
references.citation: Biol Psychiatry. 1999 Jun 15;45(12):1636-45
references.pmid: 10376126
references.citation: Addiction. 1998 May;93(5):713-27
references.pmid: 9692270
references.citation: Mil Med. 2007 Apr;172(4):359-63
references.pmid: 17484303
references.citation: Am J Psychiatry. 2005 Aug;162(8):1483-93
references.pmid: 16055769
references.citation: J Clin Psychiatry. 2003;64 Suppl 13:5-12
references.pmid: 14552650
references.citation: Arch Gen Psychiatry. 1986 Nov;43(11):1037-41
references.pmid: 3021082
references.citation: Biol Psychiatry. 2007 Apr 15;61(8):928-34
references.pmid: 17069768
references.citation: Biol Psychiatry. 1999 May 1;45(9):1226-9
references.pmid: 10331117
references.citation: Arch Intern Med. 2007 Mar 12;167(5):476-82
references.pmid: 17353495
references.citation: Expert Rev Neurother. 2007 Jun;7(6):603-15
references.pmid: 17563244
references.citation: Brain Res. 2009 Oct 13;1293:13-23
references.pmid: 19332037